Biotech Values

[JJM760]

Nevertheless, I've mentioned on the ARIA board before that I am nervous about its approval chances. I'm not excited about ridaforolimus' commercial potential for sarcoma either. Ponatinib is undoubtedly ARIA's crown jewel. For me, any success with ridaforolimus would be a bonus.

Agreed and I think Berger would agree otherwise I sincerely doubt he would have sold Rida to Mrk.

I was at a conference in NYC where Berger was asked about the chances of Rida approval. He responded that because Rida met its endpoints (of its designed trial) and also the obvious lack of current options for Sarcoma patients, he felt strongly that it would be approved. Now whether that is a CEO talking his book or not I guess remains to be seen. Mrk seems to agree and for what it's worth, so do I.

We will know fairly soon if the FDA and the EMA agree. Fingers crossed.